Published : 2024-02-22

SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases

Mateusz Sobczyk

Daria Żuraw

Paulina Oleksa

Kacper Jasiński

Mikołaj Porzak

Michał Dacka


Neurological diseases, neurological complications of diabetes and cardiovascular disease complications affecting the central nervous system (CNS) are one of the greatest challenges of modern medicine. Many of these diseases require the introduction of new therapies to improve the prognosis and quality of life of patients. Drugs with the increasing use in recent years are the SGLT2 inhibitors (SGLT2i): canagliflozin, dapagliflozin, empagliflozin. They demonstrate multiple pleiotropic actions with potential applications in CNS diseases. In addition to renal tubules, SGLT receptors are also found within the central nervous system. In numerous studies in animal models, SGLT2i have had promising results in the treatment of neurological conditions such as Alzheimer's disease, autism spectrum disorders, lesions caused by vascular diseases or complications of ischaemic stroke. SGLT2 inhibitors reduce oxidative stress and activation of inflammatory processes within the CNS, which may in the future be used to treat neurological diseases. So far, published studies on the effects of SGLT2 inhibitors on the nervous system are promising, but extensive, multicentre randomised trials on large groups of patients are needed to understand the exact mechanisms of action, therapeutic effects and potential side effects of SGLT2i.


SGLT2 inhibitors, Alzheimer disease, Ischemic Stroke, Type 2 Diabetes, Autism spectrum disorders

Most read articles by the same author(s)





Download files


Citation rules

Sobczyk, M., Żuraw, D., Oleksa, P., Jasiński, K., Porzak, M., & Dacka, M. (2024). SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases. Prospects in Pharmaceutical Sciences, 22(1), 16–22.

Altmetric indicators

Cited by / Share


Editorial Team
Stefana Banacha 1
02-097 Warsaw, Poland
Medical University of Warsaw
ul. Żwirki i Wigury 61
02-091 Warszawa

Copyright 2021 by
OJS Support and Customization by LIBCOM
Platform & workfow by OJS/PKP